Emergent Biosolutions, Inc. (EBS) Scheduled to Post Quarterly Earnings on Monday
Emergent Biosolutions, Inc. (NYSE:EBS) is scheduled to announce its earnings results after the market closes on Monday, November 6th. Analysts expect the company to announce earnings of $0.41 per share for the quarter.
Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $0.13 earnings per share for the quarter, missing analysts’ consensus estimates of $0.26 by ($0.13). The firm had revenue of $100.77 million during the quarter, compared to analyst estimates of $111.57 million. Emergent Biosolutions had a net margin of 13.42% and a return on equity of 14.50%. The firm’s revenue for the quarter was up 10.4% on a year-over-year basis. During the same period in the prior year, the company posted ($0.05) earnings per share. On average, analysts expect Emergent Biosolutions to post $1.48 EPS for the current fiscal year and $2.21 EPS for the next fiscal year.
Emergent Biosolutions, Inc. (NYSE EBS) opened at 40.60 on Monday. Emergent Biosolutions, Inc. has a one year low of $24.47 and a one year high of $41.46. The stock has a 50 day moving average price of $39.51 and a 200-day moving average price of $34.72. The firm has a market capitalization of $1.67 billion, a price-to-earnings ratio of 25.86 and a beta of 1.26.
EBS has been the topic of a number of research analyst reports. Zacks Investment Research cut Emergent Biosolutions from a “hold” rating to a “sell” rating in a research report on Monday, July 17th. BidaskClub cut Emergent Biosolutions from a “buy” rating to a “hold” rating in a research report on Friday, August 4th. Finally, Wells Fargo & Company reiterated an “outperform” rating and set a $43.00 target price (up previously from $41.00) on shares of Emergent Biosolutions in a research report on Saturday, September 30th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $45.00.
In related news, CEO Daniel Abdun-Nabi sold 15,000 shares of the business’s stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $37.21, for a total value of $558,150.00. Following the transaction, the chief executive officer now owns 219,134 shares in the company, valued at approximately $8,153,976.14. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jerome M. Hauer sold 10,776 shares of the business’s stock in a transaction dated Tuesday, August 15th. The shares were sold at an average price of $35.83, for a total value of $386,104.08. Following the completion of the transaction, the director now owns 29,421 shares in the company, valued at approximately $1,054,154.43. The disclosure for this sale can be found here. Insiders sold a total of 180,227 shares of company stock worth $6,993,970 in the last 90 days. 16.50% of the stock is currently owned by insiders.
Emergent Biosolutions Company Profile
Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).
Receive News & Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.